## Discovery Services

## Certificate of Analysis

## JMJD2E

## Human jumonji domain containing 2E, active

(Recombinant enzyme expressed in E.coli)
Item \# EPI033
Lot \# 139704

Product Description: $N$-terminal 6Histagged, recombinant, amino acids 1-336, human JMJD2E, expressed in E.coli. Purified using immobilised metal affinity chromatography. MW $=41.2 \mathrm{kDa}$.

Aliases: KDM4E

Formulation: $\mathbf{1 m g} / \mathrm{ml}$ of enzyme in 5 mM Hepes $/ \mathrm{NaOH} \mathrm{pH} 7.4$, $250 \mathrm{mM} \mathrm{NaCl}, 50 \%$ glycerol. Frozen solution.

Storage and Stability: Stable for 1 year at $-70^{\circ} \mathrm{C}$ from date of shipment. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled microcentrifuge tubes and store at $-70^{\circ} \mathrm{C}$.

FOR IN VITRO RESEARCH USE ONLY NOT FOR USE IN HUMANS OR ANIMALS

## Quality Control Testing

Demethylase Assay: 0.1-5ng of this lot of protein bound 300nM biotin-H3K9me3 in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.


MS: Size was confirmed by mass spectrometry using a Q-TOF.
\(\left.$$
\begin{array}{cl}\begin{array}{c}\text { KDa } \\
250\end{array} & \begin{array}{l}\text { SDS-PAGE and Coomassie } \\
\text { Stain: Purity was assessed by }\end{array} \\
150 & \begin{array}{l}\text { SDS-PAGE and Coomassie } \\
\text { blue staining using } 4 \mu \text { of } \\
\text { JMJD2E. }\end{array}
$$ <br>
100 <br>

75\end{array}\right]\)| 15 |
| :--- |
| 50 |

Eurofins Pharma
Gemini Crescent
Dundee Technology Park
DUNDEE

T| +44 (0)1382 561600
F | +44 (0)1382 561601
www.eurofins.com/pharmadiscovery

## Discovery Services

## Certificate of Analysis

## Demethylase Assay Protocol

## Stock Solutions:

1. Reaction buffer: 56 mM Hepes $\mathrm{pH} 7.0,0.0125 \%$ Tween 20, $6.25 \mu \mathrm{M}$ FAS, $125 \mu \mathrm{M}$ Ascorbic acid, $3.75 \mu \mathrm{M} 2$-Oxoglutarate, $0.0125 \%$ BSA.
2. JMJD2E, active: Dilute with reaction buffer. Use 0.1-5ng per assay point.
3. Biotin-H3K9me3: Dilute with reaction buffer to 600nM.
4. STOP solution: 4 mM EDTA.
5. Detection Mix: Dilute Eu-anti-methyl histone H3K9me2 and Ulight ${ }^{\text {TM }}$-Streptavidine in detection buffer to 4 nM and 100 nM respectively.

## Assay Procedure (384 well white plate format):

1. Add $2 \mu \mathrm{l}$ of $5 \%$ DMSO per assay to wells.
2. Add $3 \mu \mathrm{l}(0.1-5 \mathrm{ng})$ JMJD2E, active.
3. Add $5 \mu \mathrm{l}$ of Biotin-H3K9me3.
4. Incubate for 10 minutes at $22^{\circ} \mathrm{C}$.
5. Add $5 \mu \mathrm{l}$ of STOP solution.
6. Incubate for 5 minutes at $22^{\circ} \mathrm{C}$.
7. Add $5 \mu \mathrm{l}$ of Detection Mix.
8. Incubate for 60 minutes at $22^{\circ} \mathrm{C}$
9. Excite at 320 nm and read at $620 / 665 \mathrm{~nm}$. Calculate the HTRF ratio signal at $665 \mathrm{~nm} /$ signal at 620 nm x10000. Compare the signal of enzyme samples with that of a background sample that contains all assay components except the enzyme JMJD2E.

## Certificate of Analysis

## JMJD2E Sequence Information

## Protein

Human JMJD2E

Tags
N -Terminal 6His

Accession number GenBank NP_001155102

## Recombinant JMJD2E amino acid sequence:

1 MHHHHHHSSG VDLGTENLYF QSMKSVHSSP QNTSHTIMTF YPTMEEFADF
51 NTYVAYMESQ GAHQAGLAKV IPPKEWKARQ MYDDIEDILI ATPLQQVTSG
101 QGGVFTQYHK KKKAMRVGQY RRLANSKKYQ TPPHQNFADL EQRYWKSHPG
151 NPPIYGADIS GSLFEESTKQ WNLGHLGTIL DLLEQECGVV IEGVNTPYLY
201 FGMWKTTFAW HTEDMDLYSI NYLHFGEPKT WYVVPPEHGQ HLERLARELF
251 PDISRGCEAF LRHKVALISP TVLKENGIPF NCMTQEAGEF MVTFPYGYHA
301 GFNHGFNCAE AINFATPRWI DYGKMASQCS CGESTVTFSM DPFVRIVQPE
351 SYELWKHR

Reviewed and approved by site quality representative.
Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.

